AQST - Aquestive Therapeutics: Discounted With An Incredible Risk-Reward For 2022

• Aquestive Therapeutics made several advancements last year that have set the stage for a potentially transformative year in 2022. Unfortunately, the share price ended the year on a sour note.
• The FDA informed the company they will not be ready to take action on their PDUFA date. AQST’s share price fell from roughly $6 is now around $2.50.
• I believe the market has taken the selling too far considering the FDA did not provide the company a complete response letter “CRL”.
• Isee a great opportunity to accumulate some shares in anticipation the FDA willultimately approve Libervant.

For further details see: